Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571231 | 0.85 | KMT2A (0.45) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL16000110 | 0.81 | ALDH1A1 (0.45) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL13234055 | 0.80 | KMT2A (0.49) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL5121672 | 0.80 | PSIP1 (0.44) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL5121670 | 0.80 | ALDH1A1 (0.44) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL16000109 | 0.80 | KDM4E (0.50) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL18571269 | 0.80 | ALDH1A1 (0.44) | MEN1ALDH1A1HTTKMT2ANPSR1 | |
| SCHEMBL18571235 | 0.80 | KMT2A (0.44) | MEN1ALDH1A1HTTKMT2ANPSR1 | |
| SCHEMBL2993430 | 0.80 | ALDH1A1 (0.44) | CA2MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL24425775 | 0.79 | CA2 (0.50) | CA2MEN1ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332443-B2 | Derivatives of halo quinabactin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2017034982-A1 | DERIVATIVES OF HALO QUINABACTIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332443-B2 | Derivatives of halo quinabactin | HDHD5, HSF1, NQO2 | CA2 995/4885MEN1 4584/4885ALDH1A1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.